INTERMITTENT VS. CONTINUOUS OXALIPLATIN-FLUOROPYRIMIDINE CHEMOTHERAPY IN THE MRC COIN TRIAL IN ADVANCED COLORECTAL CANCER: UPDATED EFFICACY RESULTS, QUALITY OF LIFE AND POTENTIAL PREDICTIVE FACTORS

Bibliographic Details
Main Authors:	Adams, R, Wilson, R, Seymour, M, Meade, A, Madi, A, Cassidy, J, Fisher, D, Kenny, S, Kaplan, R, Maughan, T
Format:	Conference item
Published:	2010

THE IMPACT OF MILD RENAL IMPAIRMENT ON THE TOXICITY OF OXALIPLATIN AND FLUOROPYRIMIDINE REGIMENS: EXPERIENCE IN THE MRC COIN TRIAL
by: Madi, A, et al.
Published: (2010)

Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience.
by: Adams, R, et al.
Published: (2009)

Intermittent versus continuous oxaliplatin-based combination chemotherapy in patients with advanced colorectal cancer: a randomised non-inferiority trial (MRC COIN)
by: Adams, R, et al.
Published: (2009)

Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
by: Adams, R, et al.
Published: (2011)

THE ADDITION OF CETUXIMAB TO OXALIPLATIN-FLUOROPYRIMIDINE CHEMOTHERAPY IN FIRST-LINE ADVANCED COLORECTAL CANCER IN THE MRC COIN TRIAL: IDENTIFICATION OF POTENTIALLY RESPONSIVE SUBSETS OF PATIENTS
by: Maughan, T, et al.
Published: (2010)

Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial.
by: Madi, A, et al.
Published: (2012)

Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: The MRC COIN trial
by: Madi, A, et al.
Published: (2012)

Addition of cetuximab to oxaliplatin-based combination chemotherapy (CT) in patients with KRAS wild-type advanced colorectal cancer (ACRC): a randomised superiority trial (MRC COIN)
by: Maughan, T, et al.
Published: (2009)

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
by: Maughan, T, et al.
Published: (2011)

ADDITION OF CETUXIMAB TO OXALIPLATIN-BASED COMBINATION CHEMOTHERAPY (CT) IN PATIENTS WITH K-ras WILD-TYPE ADVANCED COLORECTAL CANCER (ACRC): EFFECTS ON OVERALL SURVIVAL. MRC COIN (CR10) TRIAL RESULTS
by: Adams, R, et al.
Published: (2009)

Intermittent Chemotherapy (CT) Plus Continuous or Intermittent Cetuximab (C) in the First-line Treatment of Advanced Colorectal Cancer (aCRC): Results of the Two-arm Phase II Randomised MRC COIN-B Trial
by: Wasan, H, et al.
Published: (2011)

Cetuximab therapy in first-line metastatic colorectal cancer and intermittent palliative chemotherapy: review of the COIN trial.
by: Adams, R, et al.
Published: (2008)

THROMBOCYTOSIS AS A PREDICTIVE AND PROGNOSTIC MARKER IN ADVANCED COLORECTAL CANCER (ACRC): RESULTS OF THE MRC COIN TRIAL EXPLORED
by: Maughan, T, et al.
Published: (2010)

Chemotherapy-free intervals for patients with metastatic colorectal cancer remain an option.
by: Maughan, T, et al.
Published: (2010)

3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial
by: Iveson, T, et al.
Published: (2018)

Chemotherapy choices and doses in frail and elderly patients with advanced colorectal cancer: an MRC randomised clinical trial (FOCUS2)
by: Seymour, M, et al.
Published: (2007)

Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial.
by: Maughan, T, et al.
Published: (2003)

CETUXIMAB COMBINED WITH INFUSIONAL 5-FLUOROURACIL/FOLINIC ACID AND OXALIPLATIN IN METASTATIC COLORECTAL CANCER: POOLED ANALYSIS OF COIN AND OPUS STUDY DATA
by: Taieb, J, et al.
Published: (2012)

Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.
by: Seymour, M, et al.
Published: (2007)

Derived neutrophil to lymphocyte ratio as a prognostic factor in patients with advanced colorectal cancer according to RAS and BRAF status: a post-hoc analysis of the MRC COIN study.
by: Wood, G, et al.
Published: (2017)

Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial.
by: Seymour, M, et al.
Published: (2011)

A pilot study of the use of Oxaliplatin in metastatic colorectal cancer at Velindre
by: Mitra, S, et al.
Published: (2001)

Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy
by: Madi, A, et al.
Published: (2018)

Cells deficient in the base excision repair protein, DNA polymerase beta, are hypersensitive to oxaliplatin chemotherapy.
by: Yang, J, et al.
Published: (2010)

Pattern recognition receptor polymorphisms as predictors of oxaliplatin benefit in colorectal cancer
by: Gray, V, et al.
Published: (2019)

Self-assembled oxaliplatin(IV) prodrug-porphyrin conjugate for combinational photodynamic therapy and chemotherapy
by: Lim, Wei Qi, et al.
Published: (2021)

Stratifiers for oxaliplatin outcome in colorectal cancer
by: Hassanieh, S
Published: (2021)

Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy.
by: Sharma, R, et al.
Published: (2007)

Tumour expression of the DNA repair protein, XPF, predicts pathological response to neoadjuvant oxaliplatin chemotherapy in oesophageal cancer
by: Gillies, R, et al.
Published: (2011)

Chemotherapy for older patients with colorectal cancer Reply
by: Seymour, M, et al.
Published: (2011)

Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy ± cetuximab.
by: Smith, C, et al.
Published: (2013)

Role for nucleotide-excision repair gene variants in oxaliplatin-induced peripheral neuropathy
by: West, H, et al.
Published: (2018)

Capecitabine (X) and oxaliplatin (O) combination chemotherapy in patients (pts) with advanced gall bladder or biliary tract cancer: A phase II study
by: Evans, T, et al.
Published: (2006)

XPF protein levels determine sensitivity of malignant melanoma cells to oxaliplatin chemotherapy: Suitability as a biomarker for patient selection
by: Hatch, S, et al.
Published: (2014)

XPF protein levels determine sensitivity of malignant melanoma cells to oxaliplatin chemotherapy: suitability as a biomarker for patient selection.
by: Hatch, S, et al.
Published: (2014)

Metastatic colorectal cancer: irinotecan plus infusional, bolus or oral fluoropyrimidines as first-line treatment.
by: Kerr, D
Published: (2008)

NEOSCOPE: A randomised phase II study of induction chemotherapy followed by oxaliplatin/capecitabine or carboplatin/paclitaxel based pre-operative chemoradiation for resectable oesophageal adenocarcinoma
by: Mukherjee, S, et al.
Published: (2017)

Translational study identifies XPF and MUS81 as predictive biomarkers for oxaliplatin-based peri-operative chemotherapy in patients with esophageal adenocarcinoma
by: MacGregor, T, et al.
Published: (2018)

Can upfront DPYD extended variant testing reduce toxicity and associated hospital costs of fluoropyrimidine chemotherapy? A propensity score matched analysis of 2022 UK patients
by: Tsiachristas, A, et al.
Published: (2022)

Comparison of allogeneic transplant versus chemotherapy for relapsed childhood acute lymphoblastic leukaemia in the MRC UKALL R1 trial. MRC Childhood Leukaemia Working Party.
by: Harrison, G, et al.
Published: (2000)

INTERMITTENT VS. CONTINUOUS OXALIPLATIN-FLUOROPYRIMIDINE CHEMOTHERAPY IN THE MRC COIN TRIAL IN ADVANCED COLORECTAL CANCER: UPDATED EFFICACY RESULTS, QUALITY OF LIFE AND POTENTIAL PREDICTIVE FACTORS

Similar Items

Similar Items